PROCEPT Biorobotics Corp. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: PROCEPT Biorobotics Corp. (PRCT)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: PROCEPT is a surgical robotics company focused on urology, specifically treating benign prostatic hyperplasia (BPH) using its proprietary Aquablation therapy. The company develops, manufactures, and sells the AquaBeam Robotic System and the next-generation HYDROS Robotic System (FDA cleared August 2024). As of December 31, 2024, the global install base reached 647 systems (505 in the U.S.).
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $224.5 million | $136.2 million |
| Gross Profit | $137.1 million | $71.0 million |
| Gross Margin | 61% | 52% |
| Net Loss | $(91.4) million | $(105.9) million |
| Operating Loss | $(96.6) million | $(109.2) million |
| Cash and Cash Equivalents | $333.7 million | $257.2 million |
| Long-Term Debt | $52.0 million | $52.0 million |
| Accumulated Deficit | $(546.0) million | $(454.6) million |
Revenue Breakdown (2024): System sales/rentals ($90.3M), Handpieces/consumables ($121.5M), Service ($12.7M).
Geographic Mix (2024): 89% U.S., 11% International.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 65% year-over-year, driven by a 53% increase in system sales and a 75% increase in handpiece/consumable sales.
- Margin Expansion: Gross margin improved from 52% to 61%, attributed to higher unit sales spreading fixed manufacturing overhead and reduced scrap/warranty costs.
- Loss Reduction: Net loss decreased by 14% ($14.5 million) despite higher operating expenses, due to significant revenue growth and increased interest income ($9.4M vs $7.3M).
- Capital Raise: In October 2024, the company completed a follow-on common stock offering raising $164.5 million net of issuance costs.
- Product Launch: Received FDA 510(k) clearance for the HYDROS Robotic System in August 2024, featuring FirstAssist AI.
Guidance, Outlook, and Risks
Management Outlook:
- Liquidity: Management believes cash and anticipated revenue are sufficient to fund operations for at least the next 12 months.
- Strategy: Focus remains on growing the install base, increasing system utilization, and expanding third-party reimbursement coverage (currently ~95% of U.S. men covered).
- Debt Covenants: The company achieved the $200 million trailing twelve-month revenue target, extending the interest-only period on its CIBC term loan.
Key Risks and Contingencies:
- Profitability: The company has a history of significant net losses and expects to continue incurring operating losses for the foreseeable future.
- Reimbursement: Revenue depends heavily on third-party payor coverage; changes in Medicare or commercial payer policies could materially impact demand.
- Supply Chain: Reliance on single-source suppliers for critical components creates vulnerability to shortages or price fluctuations.
- Regulatory: Ongoing regulatory scrutiny and potential delays in future product approvals or modifications.
- Competition: Intense competition from established medical device companies (e.g., Boston Scientific, Teleflex) offering alternative BPH treatments.
Investor Verification Checklist
- Reimbursement Status: Verify current coverage rates with major commercial payors and any pending changes to Medicare Administrative Contractor (MAC) policies.
- Debt Covenants: Confirm continued compliance with the CIBC loan agreement, specifically the minimum unrestricted cash and revenue growth covenants.
- Install Base Utilization: Assess the rate of procedure volume growth per installed system to validate the recurring revenue model from handpieces.
- HYDROS Adoption: Monitor early adoption metrics for the new HYDROS system and the exchange rate of legacy AquaBeam systems.
- Cash Burn Rate: Review the trajectory of operating cash burn relative to the $333.7 million cash balance to determine the runway for profitability.